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The distinctive odor of the breath of patients with renal failure,
usually termed the "uremic fetor," is frequently described as
ammoniacal, and its potency is generally believed to reflect the
uremic state [11. Previous attempts at breath analysis in these
patients has, however, been directed at compounds other than
ammonia, such as dimethylamine and trimethylamine, and have
been at best semiquantitative in their approach [2]. This reflects
the considerable methodological difficulties surrounding the ac-
curate measurement of these compounds on breath. When they
are present in low concentrations as part of complex mixtures, the
value of conventional methods such as gas chromatography and
mass spectrometry is limited because they usually require that the
breath is pre-concentrated [3—SI.
The selected ion flow tube (SIFT) technique is ideally suited for
the accurate measurement of trace gases, particularly when
present in complex mixtures [6—81. In contrast to conventional
mass spectrometry, in which ionization of the trace gas molecules
is achieved by electron bombardment, resulting in molecular
"cracking" that yields spectra that are difficult to interpret, the
SIFT technique exploits the method of chemical ionization.
Molecules (M) present on the breath are "soft" ionized utilizing a
precursor ion, such as H3O, which usually results in a single
product, MH, which can then be detected by a mass spectrom-
eter, thus allowing identification and quantification of trace gases
with a sensitivity of 10 to 20 ppb from a single breath exhalation
[7].
Using the SIFT technique to analyze the breath of uremic
individuals it has been possible to show that several compounds
are present, including amines and alcohols, although in quantita-
tive terms ammonia is by far the most significant abnormality [9].
The purpose of the present study was to quantify ammonia on the
breath of normal controls and a population of stable patients
treated for end-stage renal failure with CAPD. In these patients
breath ammonia was related to their urea and peritoneal kinetics.
In hemodialysis patients the reduction in breath ammonia was
studied during dialysis, and comparisons were made with whole
blood ammonia concentrations, which is not thought to be
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significantly elevated in renal failure. Further experiments were
undertaken to establish whether breath ammonia reflects the
hydrolysis of urea within the oral cavity or is a systemic indicator
of "uremia."
METHODS
Study design and subjects
Twenty-six stable CAPD patients (13 of each sex, mean age 51,
range 19 to 76) were studied while attending as out-patients for
routine urea and peritoneal kinetic studies. All patients had
normal liver function tests and no clinical evidence of liver
disease. Each patient had collected the previous 24-hour total
dialysate to allow calculation of urea nitrogen appearance, and
each underwent a peritoneal equilibration test to measure the low
molecular weight solute transfer. Breath samples were collected
between 2:00 and 3:30 p.m. after a light lunch at midday. The
majority of patients (83%) were non-smokers, and the smokers
were asked to refrain from smoking for at least thirty minutes
prior to the study. Normal controls were recruited from the same
clinical area and/or laboratory staff, and analyzed contemporane-
ously. The study was approved by the North Staffordshire Hospital
Ethics Committee.
The reduction of breath ammonia during hemodialysis was
monitored by taking samples immediately prior to commencing
treatment and then after 20, 50, 100 and 200 minutes. Coincident
samples for the assay of whole blood ammonia were taken from
the arterial line of the fistula.
The detection of urea hydrolysis within the mouth was per-
formed as follows: after obtaining a baseline breath sample, the
normal volunteers were given a 50 ml aqueous solution of urea
that was held in the oral cavity for one minute. This time period
was selected on the basis that under experimental conditions it
resulted in maximal ammonia generation within the mouth,
longer periods being associated with a reduced production. After
spitting out the solution, breath samples were obtained at three to
five minute intervals over the following 30 minutes. Two concen-
trations of urea were used, a supra-physiological solution of 700
mmol/liter, to act as a positive control, and a pathophysiological
solution of 30 mmol/liter, an amount that reflects the salivary urea
concentration found in patients with end-stage renal failure [10].
Methods of breath sampling
Samples were obtained either by collecting 3 liters of exhaled
breath into Tedlar® gas sample bags, or by exhaling directly into
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Fig. 1. Typical spectra of breath obtained from a patient with end-stage renal failure. The molecular weight (x axis) for each molecule identified is
shown at the top of each bar. Open bars represent the precursor ions (H3O, molecular wt = 19) and their water clusters. The solid bars show the counts
obtained for trace gases, such as ammonia (protonated with molecular wt = 18) and its water clusters with molecular wt of 36 and 54, or acetone
(molecular wt 59), with a single cluster at 77. The calculated concentrations of the breath of these molecules are shown in brackets in pbb.
the SIFT apparatus. The use of such sample bags, which are
specifically designed for the analysis of trace gases, was necessi-
tated by the difficulty of patients visiting the laboratory. In the
initial experiments there was a consistent discrepancy betveen the
two methods of sampling, such that direct exhalation into the
SIFT resulted in 1.5- to 2-fold greater concentration of ammonia.
It was established that this difference was due to the condensation
of breath on the surface of the sample bags, and because ammonia
is highly soluble in water, this resulted in an underestimate of the
true breath concentration. This problem was solved by reheating
and maintaining the sample bags at body temperature throughout
the sampling procedure. The time interval between collection of
breath samples into bags, their transportation to the SIFT,
reheating and analysis was typically 10 to 20 minutes, Additional
experiments confirmed that the concentration of ammonia re-
mained stable within the sample bags during this period.
Selected ion flow tube analysis of breath ammonia
Details of the principles, methods and application of SIFT in
the measurement of trace gases on the breath have been pub-
lished elsewhere [6—8]. Briefly, a sample of breath is introduced
into the flow tube at a controlled rate (200 mI/mm) and is
transported down the tube at a known velocity (70 rn/second) by
the inert helium carrier gas. Once in the tube the trace gases
interact with precursor ions, in this case H3O, which donate
protons to the trace gas molecules resulting in "soft-ionization,"
and thus the generation of characteristic ions, that is, NH4 from
NH3, without causing "cracking." Alveolar breath has a high water
content and many of these ionized molecules will form water
clusters under these conditions. In the case of ammonia this
results in NH4 (H20) and NH4 (H20)2 ions, and these can
be seen clearly on the mass spectra obtained (Fig. 1). The absolute
concentration of ammonia in the breath sample is then calculated
from the count rates of these product ions and of the H3O
precursor ions and the measured flow rates of the breath and the
helium carrier gas [7]. The technique is very sensitive with a
detection sensitivity for trace gases of 10 to 20 ppb from a single
breath exhalation. The coefficient of variation of the measured
partial pressures for consecutive sampling is less than 5%.
Dialysis dose
The dialysis dose was assessed by calculating the weekly Kt/
Vura from the 24-hour urinary and dialysate clearances, by direct
measurement of urea in urine and from each dialysate exchange.
The volume of distribution for urea was calculated from the
Watson formula for estimating body water [11]. Results are
expressed as the total weekly Kt/Vurea (peritoneal and renal
components), or for the residual renal function (RRF) alone.
Protein catabolic rate
The protein catabolic rate (PCR) was calculated using the
equation derived from detailed nitrogen balance studies in CAPD
patients: 1121
PCR (g/day) = [0.261 UA (mmollday)] + 13 + TPL (glday)
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Table 1. Mean and range of values for urea and peritoneal kinetics in
26 CAPD patients
Mean Range
Weight kg 73.4 45—122
Plasma urea mmol/liter 21.5 9.3—40.1
Plasma creatinine imol/1iter 942 398—1525
Plasma albumin g/liter 34.5 19—45
Kt/V weekly 1.88 1.16—2.86
RRF weekly 0.47 0—1.4
PCR glday 82 48.4—142.5
NPCRg/kg/day 1.13 0.55—1.74
DIPcr ratio at 4 hours 0.66 0.51—0.8
less than 50 imoI/liter, with a same sample coefficient of variation
between 3 and 5%.
Comparisons between uremics and normal controls were made
using the un-paired Student's f-test. Correlation analysis was
performed using a standard linear regression model, both for
absolute and log transformed breath ammonia values. Because
more than one variable was found to correlate with breath
ammonia, a multiple regression analysis was also performed.
RESULTS
where UA is the total (urine plus dialysate) urea appearance and
TPL is the total (urine plus dialysate) protein loss over 24 hours.
PCR was also normalized for dry body wt (NPCR).
Peritoneal equilibration test
The peritoneal equilibration test (PET) was utilized to measure
peritoneal kinetics, and this was performed as described previ-
ously [13]. Briefly, a standard four-hour dwell period was used
(first exchange of the day), using a 2.27% glucose concentration 2
liter volume exchange. The dialysate to plasma ratio of creatinine
at the completion of the four-hour dwell period, (DIPcr), was used
as the estimate of low molecular weight solute transfer. Since
glucose interfered with the assay for creatinine in a linear fashion,
concentrations for both these solutes were measured at four
hours, and the true value for creatinine was obtained by subtract-
ing the glucose concentration multiplied by a correction factor
derived locally by our laboratory (0.47). Using this method the
four hour D/Pr is a reproducible measure of low molecular
weight solute transfer across a wide range of values (0.45 to 0.9).
Analytical methods
Plasma and dialysate concentrations of urea, creatinine and
glucose were determined on an automated discrete random access
analyzer (DAX 72; Bayer Instruments, Basingstoke, UK). Urine
and dialysate total protein estimations were made using the biuret
method. Plasma albumin levels were measured using the bromo-
cresol green method. Whole blood ammonia levels were assayed
by alkalinisation using a borate buffer, which released ammonia
gas. This resulted in a color change reaction with the indicator
bromocresol green that was read by a commercially available
spectrophotometer, Ammonia Checker IT®. Using this method,
the normal concentration for whole blood ammonia nitrogen was
Breath ammonia and urea kinetics
Breath ammonia concentration was significantly elevated in
patients treated with CAPD (mean 4880 ppb; range 820 to 14700
ppb), when compared to normal controls (mean 960 ppb; range
425 to 1800), P < 0.0001. The range of breath ammonia concen-
trations observed in patients was large, and their individual values
and relationship to plasma urea concentrations are illustrated in
Figure 2. Linear regression analysis indicated that breath ammo-
nia in CAPD patients and plasma urea were positively correlated
(r = 0.49, P = 0.007). Log transformation of the breath ammonia
enhanced both the correlation, r = 0.57, and its statistical
significance, P = 0.001.
Both the mean and the range of values for urea and peritoneal
kinetics for the 26 CAPD patients are summarized in Table 1, and
reflect typical values obtained for this treatment modality. The
linear and log-linear correlations between breath ammonia and
other measures of urea and peritoneal kinetics are summarized in
Table 2. It can be seen that there is a positive correlation of breath
ammonia with plasma albumin and the NPCR but not the PCR,
and a negative correlation with the peritoneal low molecular
weight solute transfer. These correlations were similar to those
between plasma urea and NPCR or solute transfer, and were not
enhanced by log transformation of the breath ammonia. There
were no significant correlations of breath ammonia with the body
wt, with Kt/V or with residual renal function. Multiple regression
analysis confirmed that the correlation observed with NPCR was
secondary to the correlation with plasma urea, whereas the
correlations observed between solute transport and albumin were
both stronger with breath ammonia than with plasma urea.
The breath ammonia concentration fell approximately expo-
ncntially with time on hemodialysis (Fig. 3), such that by the end
of treatment it was within the normal range, typically reflecting a
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Fig. 2. Relationship between the breath ammonia content and plasma
urea in 26 stable CAPD patients. There is a significant correlation
between the log breath ammonia and plasma urea, r = 0.57 (P = 0.001).
The shaded box represents the mean 95% CI of normal values for
reference.
Abbreviations are: (N)PCR = (normalized) protein catabolic rate;
RRF, residual renal function.
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Table 2. Correlation matrix demonstrating regression coefficients (and
significance values) between breath ammonia (linear and log
transformed) and urea and peritoneal kinetics
Plasma
urea
mmol/liter
Breath
ammonia
ppb
Breath
ammonia
log transformed
Weight kg 0.06
NS
—0.012
NS
—0.13
NS
Plasma urea mmol/liter — 0.49
P = 0.007
0.57
P = 0.001
Plasma creatinine jimol/liter 0.62
P = 0.0008
0.22
NS
0.3
NS
Plasma albumin glliter 0.35
P = 0.07
0.4
p = 0.05
0.39
P = 0.05
Kt/V weekly —0.023
NS
—0.02
NS
0.02
NS
RRF weekly —0.11
NS
0.06
NS
0.04
NS
PCR g/day 0.74
P < 0.0001
0.26
NS
0.39
P = 0.053
NPCR glkg/day 0.75
P < 0.0001
0.38
P = 0.06
0.52
P = 0.007
D/P, ratio —0.43
P=0.04
—0.48
P=0.02
—0.34
NS
Fig. 3. The change in breath ammonia levels (•) that occur during
hemodialysis. The semi-log plot demonstrates that there is an exponential
reduction in breath ammonia, with a rate constant (T) of 78 minutes.
Simultaneous data obtained from a normal control under identical
conditions is shown for comparison (E).
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Fig. 4. Impact on breath ammonia due to the hydrolysis of urea within
the oral cavity. A total of 50 ml of a concentrated urea solution (700
mmol/liter) results in the rapid increase over the next 4 to 10 minutes of
breath ammonia in sequential exhalations into the SIFT (A), indicating
that hydrolysis is occurring. When this was repeated using a urea solution
typical of the concentration of saliva in end-stage renal failure (30
mmol/liter), the rise in breath ammonia was small (•, N = 3 SD), and
remained within the normal range.
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treatment to 11 2 .tmo1/liter that occurred within the first 20
minutes of treatment, and this was similar to the concentration of
ammonia on the venous side of the dialysis membrane (9 jxmol/
liter). Blood ammonia levels in control subjects were also within
the normal range.
Hydrolysis of urea within the oral cavity
Following the placement of a supra-physiological aqueous
solution of urea (50 ml of 700 mmol/liter) within the oral cavity
there was a rapid rise in the breath ammonia levels, usually to ten
times baseline values, which peaked between four and eight
minutes, and then fell back to baseline by 25 minutes (Fig. 4). This
phenomenon, which varied in its degree between individuals,
could be prevented by washing the mouth out with sterile water,
indicating that the ammonia production represented hydrolysis of
urea within the oral cavity.
The experiment was repeated using a solution of urea at a
concentration (30 mmol/liter) that would reflect the concentration
in the mouth of patients with end-stage renal failure. Breath
samples were again taken at frequent intervals using Tedlar gas
sampling bags. A small rise in breath ammonia was observed (Fig.
4), but this was still within the limits observed in the normal
population, suggesting that the higher levels of breath ammonia
seen in the CAPD patients was not a refection of hydrolysis within
the oral cavity.
90 to 95% reduction ratio. This was accompanied by a drop in the
plasma urea (35 to 10 mmol/liter), and reductions in other trace
gases on the breath including acetone, acetonitrile and the
amines. Whole blood ammonia levels were also measured prior to
and during hemodialysis. In contrast to the breath ammonia levels
which were five to twenty times higher than normal, all blood
ammonia levels (16 2 xmol/liter) were well within the normal
range (less than 50 xmol/liter). There was a significant fall during
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DISCUSSION
This study is the first description of the application of the SIFT
technique in the quantitative assessment of a metabolic syndrome.
While initially developed for the fundamental studies of ion
chemistry, the potential for this apparatus to analyze trace gases in
complex mixtures with high sensitivity points to its potential for
exploitation in the biological sciences [8]. Examples of this include
breath analysis in metabolic disorders and the detection of
xenobiotics associated with industrial or environmental exposure
[6, 7].
When applied to normal and uremic breath, SIFT analysis is
able to provide accurate and rapid quantification of ammonia
content with an accuracy not achieved by other more conventional
techniques [4]. The principal finding of this study, that breath
ammonia is substantially elevated in uremia when compared to
normal, although long suspected, has not been previously con-
firmed. While the early clinical descriptions of the uremic fetor
described it as "ammoniacal," with much emphasis on the role of
oral bacterial overgrowth in the severely debilitated and uremic
patient, later studies argued that molecules present on the breath
were of systemic origin [1, 21. However, these studies did not
address ammonia but amines, in particular trimethylamine and
dimethylamine which, although present, are at very much lower
concentrations, at least in patients already treated by dialysis.
These molecules can also be identified and quantified by the
present technique [91.
The correlations observed in this study between breath ammo-
nia and aspects of urea kinetics seem to imply that there is a
significant relationship between breath ammonia and urea metab-
olism. The strongest correlation is between breath ammonia and
plasma urea, particularly when the ammonia concentration is log
transformed, and this is not surprising since the hydrolysis of urea
throughout the gastrointestinal tract is an important, but by no
means the exclusive source of ammonia in the human [14]. While
urea hydrolysis is enhanced as part of the normal adaptation to
low protein intakes [15, 16], perhaps leading to a significant
recycling of urea nitrogen, this remains controversial in uremic
individuals [17—19]. In this context the lack of correlation between
breath ammonia and PCR, even when the former was log
transformed, is a little surprising, since there is such a close
mathematical relationship and hence strong correlation between
PCR and plasma urea in CAPD patients. However, when the PCR
was normalized to body wt the correlation with breath ammonia
concentration, particularly when the latter was log transformed
(Table 2), becomes significant, suggesting that the relationship is
not simply a function of relationship to plasma urea. The associ-
ations observed between breath ammonia and albumin or the
peritoneal low molecular weight solute transfer are similar to
those seen with urea, although if anything of greater statistical
significance, implying a common factor in the relationship rather
than direct causality. These data, combined with the total lack of
correlations with estimates of urea clearance (Kt/V and RRF),
suggest that the breath ammonia concentration of particular
CAI'D patients is related to those aspects of urea kinetics
associated with nutritional state and protein intake rather than
dialysis dose.
One possible cause for concern in the determination of breath
ammonia concentration would be the potential influence of
smoking. Cigarette smoke contains ammonia, a fact that has been
previously documented by the SIFT technique, although the
concentrations of ammonia in the breath of smokers are consid-
erably less than we observed on the breath of our patients [20].
The majority (83%) of the patients we studied were non-smokers,
a fact that we could confirm due to the lack of acetonitrile on their
breath, a molecule that is detectable on the breath of smokers up
to seven days after their last cigarette [211. Those smokers in this
study had refrained for at least 30 minutes prior to sampling, and
previous investigations in normal smokers using SIFT have dem-
onstrated that ammonia levels on the breath are not elevated at
this stage [22].
Another aim of this study was to establish whether breath
ammonia was principally determined by the hydrolysis of urea
within the oral cavity, or whether it represented a more systemic
phenomenon. Three types of evidence would suggest it is the
latter. Firstly, the effect of the dead space (which is on average 300
mls), was minimized by taking three liter samples of breath,
thereby insuring a predominantly alveolar sample. The SIFT is
routinely used to analyze the water content of the breath sample,
and the consistently high water vapor partial pressure observed in
those samples collected in bags are in keeping with their being
representative of alveolar breath. In fact if all the ammonia
obtained in these 3 liter samples of breath from those patients
with particularly high levels were being produced within the oral
cavity, this would imply a local partial pressure of about 200 ppm
which would be sufficient to cause local chemical irritation.
Secondly, the near exponential reduction in the breath ammo-
nia during hemodialysis seems unlikely to be due to a proportional
reduction in the production of ammonia within the mouth. The
drop in ammonia was paralleled by other molecules not produced
in the mouth such as acetone and acetonitrile (present on the
breath of smokers), again indicating that the samples were
predominantly alveolar breath. It cannot, however, be entirely
ruled out that the rapid reduction in the blood—and thus salivary
urea content—during hemodialysis resulted in an immediate and
proportionate reduction in the rate of hydrolysis in the mouth,
thus influencing to some extent the total breath ammonia concen-
trations [101.
Thirdly, attempts were made to simulate the concentration of
urea that could be achieved within saliva in patients with renal
failure [10], to establish whether this could result in ammonia
production sufficient to account for the levels seen on uremic
breath. This was not found to be the case, especially when breath
samples were collected into sample bags. It should be noted that
increased numbers of bacteria may be present in the mouth in
uremics, as has been described for the upper gastrointestinal tract
[23], which could represent an additional source of ammonia.
While it appears that the elevated breath ammonia levels
cannot he explained by the hydrolysis or urea within the mouth,
they are clearly not a simple reflection of blood ammonia levels.
Indeed, it would be extremely surprising if they were, for if there
was a direct linear relationship between breath and blood ammo-
nia, then some of these patients would have been in hyper-
ammoniacal coma. Few studies have specifically measured arterial
whole blood ammonia in chronic renal failure, and although
slightly elevated levels have been reported, this is not a consistent
finding and not significant when compared to the breath levels
[24]. The problem of explaining how these high concentrations of
ammonia in breath are generated remains unresolved at this time.
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It is undoubtedly the case that the rapid and accurate ability of
the SIFT technique both to identify and quantify trace gases, such
as we have demonstrated for ammonia in renal failure, represents
a remarkable advance in the science of breath analysis. Perhaps
what is less clear is how this technique may be exploited in the
clinical investigation and management of uremia. Apart from
providing us with the first truly accurate picture of the uremic
fetor, which may be altered by different diets, the mode of dialysis
and any residual renal function, it may well provide us with a new
tool to investigate the uremic syndrome. Altered taste is a
common symptom in renal failure, which has a detrimental effect
on patient appetite, and it is easy to see that this may be
influenced by the uremic fetor, itself a cause of social distress to
some patients. Improved understanding of what constitutes and
effects the breath of these patients may well yield clinical benefits.
This technique could also be developed as a non-invasive method
of monitoring hemodialysis adequacy, due to the immediate
availability of analytical data, the ease of sample collection, and
the real potential for breath metabolites such as ammonia to act
as "uremic" markers. It is recognized that urea remains a surro-
gate marker for uremia only, despite the current emphasis of its
use in urea kinetic modelling to monitor dialysis therapy, and
problems remain in the estimation of its volume of distribution.
Analysis of breath metabolites, or even their loss through skin,
may allow the examination of solute removal from body compart-
ments other than the plasma volume, and so enhance our
assessment of dialysis adequacy.
It is also important to realize that in this preliminary report we
have evaluated this technique in its simplest mode of operation.
Tests may be specifically designed to investigate various aspects of
metabolism. For example, the SIFT is able to quantify not only
different molecules, but also their naturally occurring isotopic
variants. The current gold standard for the measurement of total
body water involves the ingestion and equilibration of D20 [25], a
method that could be refined by rapid serial measurements while
the D/H isotopes equilibrate in the water vapour on the breath.
Another possible adaptation of the technique is the non-invasive
investigation of infection with Helicobacterpylori, which is known
to increase the gastric ammonia content in uremic individuals
[261. Preliminary experiments in normal individuals with this
infection have shown an identifiable rise in the breath ammonia 20
to 30 minutes after the ingestion of urea [201.
Clearly, further research is required to realize the full potential
of this technique and to understand the factors determining
breath ammonia, but this study has shown for the first time that
the possibility of taking a quantitative approach to uremic breath
is now a practical option.
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